Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

MicroC

Financiado

Cerrado

Agent Based Modelling of Gene Networks to model clonal selection in the tumour m...

Agent Based Modelling of Gene Networks to model clonal selection in the tumour microenvironment and predict therapeutic resistance The occurrence of therapeutic resistance is a major cause for the small effect on overall survival showed by targeted cancer therapies. Whilst experimental strategies to evaluate available treatments have been faced by an ever inc... ver más

30/11/2024

2M€

Presupuesto del proyecto: 2M€

Líder del proyecto

UNIVERSITA COMMERCIALE LUIGI BOCCONI No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Fecha límite participación Sin fecha límite de participación.

Ver 3 Participantes

Financiación concedida El organismo H2020 notifico la concesión del proyecto el día 2024-11-30

ERC-2017-COG: ERC Consolidator Grant

I+D

Cerrada hace 7 años

0% 100% 100%

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

3 Participantes

455.98K€ | Lider

ALBATROS, SL

657.47K€ | Participante

UOXF

1.54M€ | Participante

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Proyectos interesantes

3DTUMOUR Development of a high throughput microplate based device to... 150K€ Cerrado

PID2021-126051OB-C43 EFECTO DE LA ANGIOGENESIS Y DE LA MODULACION INMUNE EN EL CR... 145K€ Cerrado

DARC MATTER Dynamics of Adaptation and Resistance in Cancer: MApping and... 2M€ Cerrado

Tx-phylogeography High throughput phylogeography of tumors: how the tissue en... 2M€ Cerrado

HeteroCancerInvasion Effect of heterogeneity of cancer cells on collective invasi... 195K€ Cerrado

PID2021-126051OB-C41 CARACTERIZACION IN VITRO DE LA INTERACCION ENTRE CELULAS INM... 186K€ Cerrado

Duración del proyecto: 80 meses Fecha Inicio: 2018-03-07
Fecha Fin: 2024-11-30

Líder del proyecto

UNIVERSITA COMMERCIALE LUIGI BOCCONI No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Presupuesto del proyecto 2M€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto The occurrence of therapeutic resistance is a major cause for the small effect on overall survival showed by targeted cancer therapies. Whilst experimental strategies to evaluate available treatments have been faced by an ever increasing number of possible combinations, computational approaches have been challenged by the lack of a framework able to model the multiple interactions encompassed by the three major factors affecting therapeutic resistance: selection of resistant clones, adaptability of gene signalling networks, and a protective and hypoxic tumour microenvironment. Here I propose a novel modelling framework, Agent-Based Modelling of Gene Networks, which brings together powerful computational modelling techniques and gene networks. This combination allows biological hypotheses to be tested in a controlled stepwise fashion, and it lends itself naturally to model a heterogeneous population of cells acting and evolving in a dynamic microenvironment, which is needed to predict therapeutic resistance and guide effective treatment selection. Using triple negative breast cancer (TNBC) as a testing case (15% of breast cancers, lacks validated), I propose to: 1. Develop a computational model of the TNBC tumour microenvironment using in-vitro and in-vivo, including patient-derived, models and data from clinical samples. 2. Validate the ability of the model to predict driver genes conferring a survival advantage to cancer cells in a hypoxic microenvironment. 3. Predict combinations of druggable targets to tackle TNBC therapeutic resistance. 4. Select most effective drug combinations and validate pre-clinically. This project will deliver pre-clinically validated drug combinations, new therapeutic targets and a virtual environment to study individual tumours and predict therapeutic resistance. Complementing and empowering experimental models and assays, microC will offer a new powerful tool for diagnosis and therapy.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores